Cytek Biosciences, a US-based provider of instruments for researchers and clinicians, has secured an undisclosed sum in a round co-anchored by two China-focused funds while Chinese brand promotion platform Shopal raised Rmb200 million ($29.17 million) in Series B+ round.
Northern Light, 3E Bioventures co-lead Cytek’s Series C
China-focused venture capital firm Northern Light Venture Capital and Beijing-based healthcare-focused fund 3E Bioventures Capital have co-anchored the Series C funding round of Cytek Biosciences, a US-based manufacturer and supplier of flow cytometry products and services.
Flow cytometry is a technology that is used to analyse the physical and chemical characteristics of particles in a fluid and Cytek supplies this technology to researchers and clinicians all over the world.
The amount raised in the Series C funding round was not disclosed but Cytek said it will use the fresh funds to facilitate the expansion of its global footprint and to ramp up sales, marketing, operations, and global product offerings.
As part of the investment deal, Northern Light Venture Capital founder Feng Deng will join Cytek’s board of directors.
Chinese luxury brand accelerator Shopal raises $29.17m in Series B+
Youngor Group Company Limited, a Chinese textiles and clothing enterprise, has led the Rmb200 million ($29.17 million) Series B+ funding round in Shopal, a solution provider for online and offline retailers in China.
Shopal, founded in 2017, is considered in China as the fastest growing and most professional New Luxury Brand accelerator, backed by Cathay Capital and Lianjie Capital.
According to a China Money Network report, Shopal will use the proceeds of this round to promote its self-owned high-end brand Bonnie & Clyde and expand its new luxury brand landscape.
Founded by Lu Guo, Shopal has so far closed two funding rounds. It closed an undisclosed Series B financing round in May led by Cathay Capital and Hong Kong-based Lianjie Capital.